Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC) : a case report
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Zhonghua zhong liu za zhi [Chinese journal of oncology - 42(2020), 12 vom: 23. Dez., Seite 1047-1048 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Tan, K X [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 11.01.2021 Date Revised 11.01.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn112152-20200116-00042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319070107 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319070107 | ||
| 003 | DE-627 | ||
| 005 | 20231225170657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn112152-20200116-00042 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319070107 | ||
| 035 | |a (NLM)33342162 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Tan, K X |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC) |b a case report |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2021 | ||
| 500 | |a Date Revised 11.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Carcinoma, non-small cell lung | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Nivolumab | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 700 | 1 | |a Li, C Y |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, J Y |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, H J |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, W |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, X |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, C Y |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, X J |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, S Y |e verfasserin |4 aut | |
| 700 | 1 | |a Li, J |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, C X |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua zhong liu za zhi [Chinese journal of oncology |d 1989 |g 42(2020), 12 vom: 23. Dez., Seite 1047-1048 |w (DE-627)NLM000961434 |x 0253-3766 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2020 |g number:12 |g day:23 |g month:12 |g pages:1047-1048 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn112152-20200116-00042 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2020 |e 12 |b 23 |c 12 |h 1047-1048 | ||